About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Walter L. Way, RPh, MD, and Fred S. Mayer, RPh, MPH
Presentations cover a short course of treatment with capecitabine (Xeloda), docetaxel (Taxotere), and trastuzumab (Herceptin); a study of the aromatase inhibitors letrozole (Femara) and zoledronic acid (Zometa) and their effect on bone loss; the aromatase inhibitors and tamoxifen (Nolvadex); and a trial of capecitabine plus ixabepilone (Ixempra) compared with ixabepilone monotherapy.
Topics include two new agents: ciclesonide (Alvesco Inhalation Aerosol) for the maintenance treatment of asthma and etravirine (Intelence) for adults with HIV infection. A new indication for colesevelam (Welchol) to improve glycemic control in type-2 diabetes is also discussed.
Marvin M. Goldenberg, PhD, RPh, MS
The authors conducted a study to determine whether patients who were not using insulin were following guidelines for self-monitoring of blood glucose. After a new software package was implemented at their institution, the reduced number of excess test strips led to cost savings and improved compliance.
Anita D. Patel, BA, PharmD; Viktoria Kharlamb, PharmD; Arthur P. Reiter, BS, MS; and Ron Lovly, MS, RPh
Continuing Education Credit
The authors describe the pathophysiology and pharmacotherapy of a common complication of diabetes that causes significant morbidity and mortality.
Erin L. St. Onge, PharmD, and Shannon A. Miller, PharmD
David Nash, MD, MBA, discusses a new report on the government’s efforts to provide improved health care to diabetic patients.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, suggests that a traditional evidence-based approach cannot be the only way to promote patient safety; common sense is also essential.
Matthew Grissinger, RPh, FASCP
Stephen Barlas details the FDA’s current problems, including an unstable leadership, a lack of manpower, poor morale, too little research, and critical gaps in scientific expertise and technology.
From alendronate to Simcor, P&T presents the latest information on FDA approvals, recalls, and industry updates.
The authors review doripenem (Doribax), a carbapenem antibacterial agent.
Olga Hilas, PharmD, BCPS, CGP; Danielle C. Ezzo, PharmD, BCPS; and Tomasz Z. Jodlowski, PharmD, BCPS